ADTX
Aditxt, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
0.01
DCF Value
$-474.52
FCF Yield
-1600379950.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
8.4%
Operating Margin
-612542.2%
Net Margin
-1349028.2%
ROE
-3061.4%
ROA
-261.0%
ROIC
-281.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.2M | $-43.06B | $702.12 |
| FY 2025 | $3.2M | $-43.10B | $-1,153.83 |
| Q3 2025 | $748.00 | $-24.0M | $-548.78 |
| Q2 2025 | $1.0K | $-7.3M | $-390.17 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.51
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.